HOME >> BIOLOGY >> NEWS
Molecular marker predicts success of breast cancer treatment

A new study demonstrates that the ratio of the expression levels of two genes can be used to accurately predict the clinical outcome of tamoxifen treatment for early stage breast cancer. It is the first method to reliably differentiate between patients who experienced disease-free survival and those at risk for tumor recurrence. The findings also provide new insight into the molecular mechanisms that may contribute to tamoxifen resistance.

Tamoxifen is one of the most widely used therapies for breast cancer. It works by blocking the action of estrogen on breast cancer cells. Estrogen directs the growth of normal breast cells, but can also stimulate the abnormal and unregulated cell growth associated with breast cancer. Unfortunately, nearly 40% of breast cancer patients fail to respond to tamoxifen or eventually become resistant to treatment, and there is no reliable way to predict treatment outcome. Dr. Dennis C. Sgroi from the Pathology Department at Massachusetts General Hospital and Dr. Mark G. Erlander from Arcturus Bioscience, Inc. in Mountain View, California examined the gene expression levels in 60 breast cancers from patients who were treated with tamoxifen after their surgery. Measuring gene expression is a way to examine whether or not a gene is functioning. They discovered that the ratio of the expression levels of two genes, HOXB13 and IL17BR, accurately predicted whether tumors reoccurred after treatment with tamoxifen. The researchers also found that when HOXB13 levels were experimentally elevated in cells from normal breast tissue cultured in the laboratory, the cells showed obvious morphological changes and became more invasive in response to growth signals. "This suggests that HOXB13 may directly contribute to tumor invasion and metastasis," explains Dr. Sgroi.

The researchers conclude that the HOXB13:IL17BR expression ratio may provide an effective molecular marker for identifying breast cancer patients who will be less likely to
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
3-Jun-2004


Page: 1 2

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular image of genotoxin reveals how bacteria damage human DNA
10. Molecular mechanism found that may improve ability of stem cells to fight disease
11. Molecular midwives hold clues to the origin of life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/5/2019)... Calif. (PRWEB) , ... July 05, 2019 , ... ... with Microsoft to bring its patented Tractus™ Platform to governments around the world. ... bring cutting edge technology and point of care solutions to operating theatres worldwide ...
(Date:6/20/2019)... ... June 19, 2019 , ... The half-million dollars ... of America Foundation, and the possibly millions of dollars of “high priority” grants ... AD, are a “welcome affirmation” of the need to investigate more thoroughly the ...
(Date:6/16/2019)... ... , ... Emtec, Inc.®, a global IT and management consulting ... CIO at the Healthcare Industry User Group (HIUG) Interact 2019 in ... President and Chief Information Officer, Lynne Briggs, will present Versiti’s Oracle Cloud Success ...
Breaking Biology News(10 mins):
(Date:7/2/2019)... ... July 02, 2019 , ... Leading Regenerative Veterinary Medicine ... Pharm: Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as ... Animal Pharm was recently included in the Brentwood and Pacific Palisades International ...
(Date:6/12/2019)... TOWNSHIP, N.J. (PRWEB) , ... June 12, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... with Shanghai Zillion has been signed. The agreement will grant exclusive rights for ...
(Date:6/11/2019)... ROANOKE, Va. (PRWEB) , ... June 11, 2019 ... ... for microlearning engagement, and Carilion Clinic, a national leader in opioid treatment, announced ... in virtual care. , Mytonomy recently deployed its virtual care platform ...
(Date:5/31/2019)... ... ... For many years, the primary forms of cancer treatment have been chemotherapy, radiation ... have led to the advent of Chimeric Antigen Receptor T (CAR T) cell therapy, ... “CARs”. The CAR enables the final product to produce chemicals in the hopes that ...
Breaking Biology Technology:
Cached News: